Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 601 - 650 of 1868 results
- Mannan-mediated gene delivery for cancer immunotherapy.
- Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.
- The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer.
- Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.
- Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
- Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
- Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.
- Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
- Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.
- Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells.
- Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.
- Development and characterization of novel photosensitizer : scFv conjugates for use in photodynamic therapy of cancer.
- Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity.
- Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
- Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
- Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
- VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model.
- Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages.
- Endogenous IL-12 triggers an antiangiogenic program in melanoma cells.
- A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
- Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies.
- Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
- A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
- Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis.
- A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
- Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
- Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
- Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
- CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis.
- Delivery of antigen to CD40 induces protective immune responses against tumors.
- Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance.
- Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines.
- Defective antitumor responses in CX3CR1-deficient mice.
- TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
- Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
- Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer.
- Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
- CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
- Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia.
- Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies.
- Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.
- IL-28 elicits antitumor responses against murine fibrosarcoma.
- Tumor-released microvesicles as vehicles of immunosuppression.
- Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
- IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.
- Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
- Therapeutic effect of pEgr-IL18-B7.2 gene radiotherapy in B16 melanoma-bearing mice.
- Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells.
- New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.
- The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells.